Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of DFD-03 vs Tazorac in Moderate Acne
NCT03599193Phase 2Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tazarotene in acne vulgaris (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Maximum Plasma Concentration at Day 21, Area Under the Curve at Steady State at Day 21 and 1 more. Started Oct 2017; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03599193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599193.